Biote Reports Q4 Revenue of $46.4M, Beating Expectations
Reports Q4 revenue $46.4M, consensus $45.8M. "Over the past twelve months, Biote has focused on our strategic priorities which are designed to drive sustainable profitable growth and create long-term value for stockholders," said Bret Christensen, CEO. "Through our decisive actions, we are rebuilding and expanding our commercial sales coverage, strengthening our relationships with top-tier providers and instilling a high-performance culture that empowers our team to scale our business efficiently. While our commercial transition impacted our overall financial performance in 2025 as we expected, we anticipate a return to procedure revenue growth in the second half of 2026. Our fourth quarter financial results reflected our disciplined execution as we implemented enhancements to our business operations. While I am pleased with the progress we have achieved so far, we still have work to do to optimize our performance and reach our strategic objectives. I remain confident we are on the right path to further strengthen our capabilities, advance patient health and wellness, and drive sustainable long-term growth."
Trade with 70% Backtested Accuracy
Analyst Views on BTMD
About BTMD
About the author
Biote Corp. Q4 2025 Earnings Call Insights
- Sales Team Expansion: Biote Corp. reported that its sales team grew to over 90 members by the end of 2025, up from 60 prior to the reorganization, successfully stabilizing clinic attrition and maximizing new clinic starts, indicating positive progress in rebuilding its commercial team.
- Financial Performance Overview: The fourth quarter revenue was $46.4 million, with procedure revenue declining 13% to $31.8 million, while dietary supplement revenue grew 16% to $11.7 million, providing a new revenue stream despite the overall decline in revenue.
- Future Outlook: The company forecasts revenues exceeding $190 million and adjusted EBITDA above $38 million for 2026, with a projected decline in procedure revenue in the first half but anticipated growth in the second half, reflecting management's cautious optimism about future performance.
- Investments and Expenses: Management plans to increase sales personnel to approximately 120 in 2026 and make significant investments in the technology platform, which will lead to a near-term rise in operating expenses but is expected to lay the groundwork for future growth in procedure revenue.
BIOTE Releases Financial Outlook for 2026
- Earnings Highlights: BIOTE's Q4 GAAP EPS of $0.06 exceeded expectations by $0.04, while revenue of $46.4 million, despite a 6.9% year-over-year decline, beat estimates by $0.61 million, demonstrating the company's resilience in challenging conditions.
- 2026 Revenue Outlook: The company anticipates total revenue exceeding $190 million in 2026, with procedure revenue expected to decline at a mid to high single-digit percentage rate in the first half, but projected to return to growth in the second half, indicating potential market recovery.
- Adjusted EBITDA Guidance: BIOTE expects adjusted EBITDA to exceed $38 million in 2026, reflecting ongoing efforts in cost control and operational efficiency aimed at enhancing profitability and boosting investor confidence.
- Nutritional Supplements Growth: Revenue from dietary supplements is expected to grow at a mid to high single-digit rate in 2026, indicating the company's strong positioning in the health and nutrition sector to capitalize on the increasing consumer demand for health products.
Biote Corp Reports Decrease in Q3 Earnings
- Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
- Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
- Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
- Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?
Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.
Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.
Biote Names Rich Barrera to Board of Directors
New Board Member Announcement: Biote Corp. has appointed Rich Barrera to its Board of Directors, bringing over 20 years of investment management experience and alignment with the company's growth strategy.
Company Overview: Biote focuses on preventive health care through personalized hormone optimization and wellness solutions, aiming to address aging conditions and enhance clinic success for practitioners.
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Meta Platforms Earnings Report: Meta Platforms, Inc. shares rose 6.1% in pre-market trading after reporting first-quarter earnings of $6.43 per share, significantly exceeding analyst expectations of $5.21, and projecting second-quarter revenue between $42.5 billion and $45.5 billion.
Stock Movements: Several stocks experienced notable changes in pre-market trading, with NanoVibronix, Inc. rising 81.8% and biote Corp. falling 46%, while Microsoft Corporation also saw an 8.2% increase following better-than-expected financial results.
Biote Corp. Q4 2025 Earnings Call Insights
- Sales Team Expansion: Biote Corp. reported that its sales team grew to over 90 members by the end of 2025, up from 60 prior to the reorganization, successfully stabilizing clinic attrition and maximizing new clinic starts, indicating positive progress in rebuilding its commercial team.
- Financial Performance Overview: The fourth quarter revenue was $46.4 million, with procedure revenue declining 13% to $31.8 million, while dietary supplement revenue grew 16% to $11.7 million, providing a new revenue stream despite the overall decline in revenue.
- Future Outlook: The company forecasts revenues exceeding $190 million and adjusted EBITDA above $38 million for 2026, with a projected decline in procedure revenue in the first half but anticipated growth in the second half, reflecting management's cautious optimism about future performance.
- Investments and Expenses: Management plans to increase sales personnel to approximately 120 in 2026 and make significant investments in the technology platform, which will lead to a near-term rise in operating expenses but is expected to lay the groundwork for future growth in procedure revenue.
BIOTE Releases Financial Outlook for 2026
- Earnings Highlights: BIOTE's Q4 GAAP EPS of $0.06 exceeded expectations by $0.04, while revenue of $46.4 million, despite a 6.9% year-over-year decline, beat estimates by $0.61 million, demonstrating the company's resilience in challenging conditions.
- 2026 Revenue Outlook: The company anticipates total revenue exceeding $190 million in 2026, with procedure revenue expected to decline at a mid to high single-digit percentage rate in the first half, but projected to return to growth in the second half, indicating potential market recovery.
- Adjusted EBITDA Guidance: BIOTE expects adjusted EBITDA to exceed $38 million in 2026, reflecting ongoing efforts in cost control and operational efficiency aimed at enhancing profitability and boosting investor confidence.
- Nutritional Supplements Growth: Revenue from dietary supplements is expected to grow at a mid to high single-digit rate in 2026, indicating the company's strong positioning in the health and nutrition sector to capitalize on the increasing consumer demand for health products.
Biote Corp Reports Decrease in Q3 Earnings
- Earnings Decline: biote Corp reported a third-quarter profit of $8.19 million, down from $10.70 million in the same period last year.
- Earnings Per Share: The earnings per share (EPS) decreased to $0.22 from $0.33 year-over-year.
- Revenue Drop: The company's revenue fell by 6.7% to $47.96 million, compared to $51.38 million in the previous year.
- Financial Overview: Key financial metrics indicate a decline in both earnings and revenue for biote Corp compared to the prior year.
Capricor (CAPR) Rises 5.3%: Could This Signal More Upside Ahead?
Capricor Therapeutics Stock Performance: Capricor Therapeutics (CAPR) shares rose 5.3% to $6.52, driven by a positive regulatory update on its Deramiocel program for Duchenne muscular dystrophy, which may expedite the drug's market entry.
Earnings Expectations and Market Position: The company is projected to report a quarterly loss of $0.54 per share, with revenues expected to increase by 6.2% year-over-year. The consensus EPS estimate has remained stable, indicating potential stock price movements may depend on future earnings revisions.
Biote Names Rich Barrera to Board of Directors
New Board Member Announcement: Biote Corp. has appointed Rich Barrera to its Board of Directors, bringing over 20 years of investment management experience and alignment with the company's growth strategy.
Company Overview: Biote focuses on preventive health care through personalized hormone optimization and wellness solutions, aiming to address aging conditions and enhance clinic success for practitioners.
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Meta Platforms Earnings Report: Meta Platforms, Inc. shares rose 6.1% in pre-market trading after reporting first-quarter earnings of $6.43 per share, significantly exceeding analyst expectations of $5.21, and projecting second-quarter revenue between $42.5 billion and $45.5 billion.
Stock Movements: Several stocks experienced notable changes in pre-market trading, with NanoVibronix, Inc. rising 81.8% and biote Corp. falling 46%, while Microsoft Corporation also saw an 8.2% increase following better-than-expected financial results.
